- Home
- GH
as 09-15-2025 12:31pm EST
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | PALO ALTO |
| Market Cap: | 4.9B | IPO Year: | 2018 |
| Target Price: | $58.24 | AVG Volume (30 days): | 2.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 17 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.35 | EPS Growth: | N/A |
| 52 Week Low/High: | $20.14 - $68.00 | Next Earning Date: | 11-05-2025 |
| Revenue: | $828,849,000 | Revenue Growth: | 28.74% |
| Revenue Growth (this year): | 28.07% | Revenue Growth (next year): | 21.61% |
Stock Insider Trading Activity of Guardant Health Inc. (GH)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Eltoukhy Helmy | GH | Co-Chief Executive Officer | Sep 9 '25 | Sell | $59.69 | 300,000 | $17,835,995.20 | 2,128,776 | |
| Joyce Meghan V. | GH | Director | Sep 2 '25 | Sell | $65.84 | 100 | $6,584.00 | 11,183 | |
| Kalia Kumud | GH | Chief Information Officer | Aug 21 '25 | Sell | $61.76 | 2,000 | $123,510.00 | 18,500 | |
| Tariq Musa | GH | N/A | Aug 19 '25 | Sell | $59.02 | 116 | $6,846.32 | 7,458 | |
| POTTER MYRTLE S | GH | N/A | Aug 19 '25 | Sell | $59.02 | 26 | $1,534.52 | 18,239 | |
| Tariq Musa | GH | Director | Jun 18 '25 | Sell | $49.47 | 3,213 | $158,947.11 | 7,458 | |
| CLARK IAN T | GH | Director | Jun 17 '25 | Sell | $48.38 | 6,672 | $322,818.72 | 9,851 |
Latest Guardant Health Inc. News
GH Breaking Stock News: Dive into GH Ticker-Specific Updates for Smart Investing
Barrons.com
4 days ago
More Blood Tests for Cancer Hit the Market
MT Newswires
4 days ago
Guardant Health, LabFlorida Deal Expands Access to Colorectal Cancer Blood Test Among Senior Communities
Business Wire
4 days ago
Guardant Health Expands Access to Shield CRC Blood Test to Senior Living Communities with LabFlorida Partnership
StockStory
5 days ago
Select Medical, Guardant Health, Artivion, PacBio, and Intuitive Surgical Shares Are Falling, What You Need To Know
Simply Wall St.
5 days ago
Guardant Health (GH) Soars 21% After Partnership With PathGroup
StockStory
3 months ago
The Top 5 Analyst Questions From Guardant Health’s Q1 Earnings Call
Zacks
3 months ago
TEM vs. GH: Which AI in Precision Oncology Stock Has More Upside Now?
Investor's Business Daily
3 months ago
Medical Services Name Flirts With A Buy Point
Compare GH vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GH Guardant Health Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.